Company overview
Basic information
Company name
Stasista, MB
Company code
307098345
VAT code
LT100018850917
Registered address
Kaišiadorių r. sav., Žiežmarių apylinkės sen., Pakertų k., Liepų al. 8-5, LT-56262
Registration date
2025-02-18
Company age: 1 y. 8 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
New construction
Ownership form
Private without foreign capital
Mažoji bendrija Stasista
Company code: 307098345
Address: Kaišiadorių r. sav., Žiežmarių apylinkės sen., Pakertų k., Liepų al. 8-5, LT-56262
VAT code: LT100018850917
Description
This description was generated by artificial intelligence.
Stasista, MB (company code 307098345) is an operational private small partnership registered on 18 February 2025. It operates in the sector of national private non-financial companies under private ownership, with Lithuanian natural and legal persons holding more than 50% of the authorised capital and no foreign investor capital. The company is governed by a CEO only and is classified as a micro company. Its core activity is EVRK F.41.00.10, New construction. The registered address is in Pakertu village, Žiežmariu apylinkes seniunija, Kaišiadoriu district municipality, Kaunas County. In its first reporting period of 316 days in 2025, the company generated revenue of €27.3K and net profit of €4.4K, resulting in a profit margin of 16.3%. At year-end 2025, equity stood at €4.4K, total assets at €5.1K, and liabilities at €619. Staff data relate to so far in 2026, but no average employee or wage figures are provided in the available information.
Download a detailed company report
Make confident decisions with all the information about Stasista, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.